Page 20 - 《中国药房》2025年6期

zumab，and dupilumab in eosinophilic asthma：a Bayesian mepolizumab，and benralizumab added to the standard of
network meta-analysis[J]. J Allergy Clin Immunol，2023， care in adults with severe asthma in Colombia[J]. Expert
151（3）：747-755. Rev Pharmacoecon Outcomes Res，2024，24（3）：361-374.
[17] 阮俊文，周建荣，刘惟优，等. 度普利尤单抗治疗支气管 [26] MAREQUE M，CLIMENTE M，MARTINEZ-MORAGON
哮喘疗效和安全性的 Meta 分析[J]. 临床荟萃，2023，38 E，et al. Cost-effectiveness of benralizumab versus mepoli‐
（10）：869-877. zumab and dupilumab in patients with severe uncontrolled
RUAN J W，ZHOU J R，LIU W Y，et al. Meta-analysis of eosinophilic asthma in Spain[J]. J Asthma，2023，60（6）：
the efficacy and safety of dupilumab on the treatment of 1210-1220.
bronchial asthma[J]. Clin Focus，2023，38（10）：869-877. [27] XU X，SCHAEFER C，SZENDE A，et al. A cost compari‐
[18] 蔡宇良. 度普利尤单抗在治疗支气管哮喘中的疗效与安 son of benralizumab，mepolizumab，and dupilumab in pa‐
全性的Meta分析[D]. 广州：广东医科大学，2023. tients with severe asthma：a US third-party payer perspec‐
CAI Y L. Meta-analysis of efficacy and safety of dupi- tive[J]. J Manag Care Spec Pharm，2023，29（11）：1193-
lumab in the treatment of bronchial asthma[D]. Guangzhou： 1204.
Guangdong Medical University，2023. [28] TOHDA Y，MATSUMOTO H，MIYATA M，et al. Cost-
[19] AKENROYE A，LASSITER G，JACKSON J W，et al. effectiveness analysis of dupilumab among patients with
Comparative efficacy of mepolizumab，benralizumab，and oral corticosteroid-dependent uncontrolled severe asthma
dupilumab in eosinophilic asthma：a Bayesian network in Japan[J]. J Asthma，2022，59（11）：2162-2173.
meta-analysis[J]. J Allergy Clin Immunol，2022，150（5）： [29] BUENDÍA J A，PATIÑO D G. Cost-utility analysis of
1097-1105.e12. dupilumab add on therapy versus standard therapy in
[20] ANDO K，FUKUDA Y，TANAKA A，et al. Comparative adolescents and adults for severe asthma in Colombia[J].
efficacy and safety of tezepelumab and other biologics in Expert Rev Pharmacoecon Outcomes Res，2022，22（4）：
patients with inadequately controlled asthma according to 575-580.
thresholds of type 2 inflammatory biomarkers：a syste- [30] BUENDÍA J A，PATIÑO D G. Dupilumab in children with
matic review and network meta-analysis[J]. Cells，2022， moderate-to-severe asthma：a cost utility analysis[J]. Pediatr
11（5）：819. Pulmonol，2022，57（10）：2313-2319.
[21] ZAAZOUEE M S，ALWARRAQI A G，MOHAMMED Y [31] HOLGUIN F，CARDET J C，CHUNG K F，et al. Manage‐
A，et al. Dupilumab efficacy and safety in patients with ment of severe asthma：a European Respiratory Society/
moderate to severe asthma：a systematic review and meta- American Thoracic Society guideline[J]. Eur Respir J，
analysis[J]. Front Pharmacol，2022，13：992731. 2020，55（1）：1900588.
[22] ANDO K，TANAKA A，SAGARA H. Comparative effi‐ [32] 齐军，吴倩，李森，等. 哮喘控制问卷与哮喘生命质量问
cacy and safety of dupilumab and benralizumab in pa‐ 卷在哮喘患者中的应用价值研究[J]. 国际呼吸杂志，
tients with inadequately controlled asthma：a systematic 2014，34（3）：174-176.
review[J]. Int J Mol Sci，2020，21（3）：889. QI J，WU Q，LI S，et al. Application value of the asthma
[23] XIONG X F，ZHU M，WU H X，et al. Efficacy and safety control questionnaire and asthma quality of life question‐
of dupilumab for the treatment of uncontrolled asthma：a naire in patients with asthma[J]. Int J Respir，2014，34（3）：
meta-analysis of randomized clinical trials[J]. Respir Res， 174-176.
2019，20（1）：108. [33] WECHSLER M E，FORD L B，MASPERO J F，et al.
[24] ZAYED Y，KHEIRI B，BANIFADEL M，et al. Dupilumab Long-term safety and efficacy of dupilumab in patients
safety and efficacy in uncontrolled asthma：a systematic with moderate-to-severe asthma（TRAVERSE）：an open-
review and meta-analysis of randomized clinical trials[J]. label extension study[J]. Lancet Respir Med，2022，10（1）：
J Asthma，2019，56（10）：1110-1119. 11-25.
[25] ALI A，GARCÍA E，TORRES-DUQUE C A，et al. Cost- （收稿日期：2024-09-23 修回日期：2025-01-15）
effectiveness analysis of dupilumab versus omalizumab， （编辑：刘明伟）

· 654 · China Pharmacy 2025 Vol. 36 No. 6 中国药房 2025年第36卷第6期